OIPE
FEB 28 2005
PATENT & TRADEMARK OFFICE

ATTORNEY'S DOCKET NO.: **0403**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Kurt von Figura *et al.*
Serial No.:	10/775,678
Filed:	February 10, 2004
For:	DIAGNOSIS AND TREATMENT OF MULTIPLE SULFATASE DEFICIENCY AND OTHER SULFATASE DEFICIENCIES
Examiner:	Not Yet Assigned
Art Unit:	Not Yet Assigned

CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)

The undersigned hereby certifies that this document is being placed in the United States mail with first-class postage attached, addressed to Mail Stop AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the 24th day of February 2005.

Laura Lieberman

Mail Stop AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT FILED PURSUANT TO THE DUTY OF DISCLOSURE UNDER 37 CFR §§1.56, 1.97 AND 1.98

Sir:

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants request consideration of this Information Disclosure Statement.

PART I: Compliance with 37 C.F.R. §1.97

This Information Disclosure Statement has been filed before the mailing date of a first Office Action on the merits in the above-identified case.

No fee or certification is required.

PART II: Information Cited

Applicants hereby make of record in the above-identified application the information listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references. Applicants also bring to the Examiner's attention the existence of related foreign application:

Serial No.	**Filing Date**
PCT/US2004/003632	10 February 2004 (10.02.04)

PART III: Remarks

Documents cited on the attached form PTO-1449 (modified) are enclosed unless otherwise indicated on the attached form PTO-1449 (modified). It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;

2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application;

The citations for the information be printed on any patent which issues from this application.

By submitting this Information Disclosure Statement, Applicants make no representation that a search has been performed, of the extent of any search performed, or that more relevant information does not exist.

By submitting this Information Disclosure Statement, Applicants make no representation that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b).

By submitting this Information Disclosure Statement, Applicants make no representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by Applicants, the Examiner is urged to form his own conclusion regarding the relevance of the cited information.

An early and favorable action is hereby requested.

Respectfully Submitted,

Konstantinos Andrikopoulos

Konstantinos Andrikopoulos, Reg. No. 48,915
TRANSKARYOTIC THERAPIES, INC.
700 Main St.
Cambridge, MA 02139

Attorney's Docket No.: 0403
Date: February 24, 2005

FEB 2 8 2005
PATENT & TRADEMARK OFFICE

FORM PTO-1449(Modified)	ATTY. DOCKET NO.: 0403	SERIAL NO.: 10/775,678
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT: .Kurt von Figura, *et al.*	
	FILING DATE: February 10, 2004	GROUP: Not yet assigned

U.S. PATENT DOCUMENTS

Exam Init	Ref Des	Document No.	Date	Name	Class	Sub Class	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						

FOREIGN PATENT DOCUMENTS

		Country & Doc. No. (11)	Pub. Date (43)		Class	Sub Class	Translation Yes	No
	BA	WO 01/60991 A	8/23/01	PCT				
	BB							
	BC							

OTHER ART

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

	CA		Schirmer *et al.*, "Computational Analysis of Bacterial Sulfatases and their Modifying Enzymes", *Chemistry and Biology* (London), 5(8), pp. R181-R186 (August 1998).
	CB		Fay, *et al.*, "Characterization of Posttranslational Formylglycine Formation by Luminal Components of the Endoplasmic Reticulum", *Journal of Biological Chemistry*, 276(50), pp. 47021-47028, (December 14, 2001).
	CC		DATABASE EMBL, Database Accession No. BD551115, (September 18, 2002).
	CD		DATABASE EMBL, Database Accession No. ABB62912, (March 26, 2002).
	CE		DATABASE EMBL, Database Accession No. Q98BQ8, (October 1, 2001).
	CF		DATABASE EMBL, Database Accession No. AKO76022 (December 13, 2002).

OTHER ART

(Including Author, Title, Date, Pertinent Pages, Publication, Etc.)

	CG		DATABASE EMBL, Database Accession No. AAB88402, (May 23, 2001).

OIPE JC:9 FEB 28 2005 PATENT & TRADEMARK OFFICE

FORM PTO-1449(Modified)	ATTY. DOCKET NO.: 0403	SERIAL NO.: 10/775,678
LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT	APPLICANT: Kurt von Figura, *et al.*	
	FILING DATE: February 10, 2004	GROUP: Not yet assigned

	CH		DATABASE EMBL, Database Accession No. AAY95971, (December 5, 2000).
	CI		DATABASE EMBL, Database Accession No. AAAB01008987, (July 24, 2002).
	CJ		DATABASE EMBL, Database Accession No. Q9F3C7, (March 1, 2001).
	CK		DATABASE EMBL, Database Accession No. P95060, (May 1, 1997).
	CL		DATABASE EMBL, Database Accession No. Q92WL9, (December 1, 2001).
	CM		DATABASE EMBL, Database Accession No. Q93PA2, (December 1, 2001).
	CN		DATABASE EMBL, Database Accession No. Q9A921, (June 1, 2001).
	CO		Schmidt *et al.*, "A Novel Amino Acid Modification in Sulfatases that is Defective in Multiple Sulfatase Deficiency', *Cell*, 82(2), pp. 271-278, (1995).
	CP		DATABASE EMBL, Database Accession No. Q7V5N5, (October 1, 2003).
	CQ		DATABASE EMBL, Database Accession No. Q8FTJ8, (March 1, 2003).
	CR		DATABASE EMBL, Database Accession No. Q88HK3, (June 1, 2003).
	CS		Dierks *et al.*, "Multiple Sulfatase Deficiency is Caused by Mutations in the Gene Encoding the Human C_{α}-Formylglycine Generating Enyme", *Cell*, 113(4), pp. 435-444, (May 16, 2003).
	CT		

EXAMINER	DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to applicant